Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses.
The major functions of pituitary thyroid-stimulating hormone (TSH) are to maintain the biosynthesis and secretion of the thyroid hormones L-thyroxine (T4) and L-3,5,3'triidothyronine (T3). The TSH core contains two apoproteins, the alpha and beta subunits. The alpha subunit is identical to that of pituitary follitropin, pituitary lutropin and placental chorionic gonadotropin, whereas the beta subunit is unique. TSH is a glycoprotein; the glycoprotein components of the alpha and beta subunits account for more than 10% of their mass and are essential for normal thyrotropic action and intravascular kinetics. The hypothalamic tripeptide, TSH-releasing hormone (TRH) is required for optimum TSH biosynthesis, particularly as far as addition of the glycoprotein components is concerned. TRH deficiency is associated with secretion of TSH molecules that are appropriately measured in most assays but have reduced bioactivity. In previous years the TSH used in clinical practice was obtained and purified from bovine pituitaries. Bovine TSH was used to test thyroid function and to augment the uptake of radioiodine in patients with thyroid cancer. Bovine TSH has been largely abandoned as a clinical agent because of adverse immune reactions. A recombinant human TSH (rhTSH; Thyrogen), has been approved by the US FDA for diagnostic use in patients with thyroid cancer. The alpha and beta subunits of Thyrogen are identical to those of human pituitary TSH. Thyrogen has a specific activity of approximately 4 IU/mg and is a potent stimulator of T4, T3 and thyroglobulin (Tg) secretion in healthy volunteers. It also increases thyroid iodide uptake in patients with thyroid cancer or multinodular goitre and in volunteers, even those exposed to large amounts of stable iodide. Thyroid cancer patients who have been treated by thyroidectomy and radioiodine ablation but are at risk of harbouring residual thyroid cancer are candidates for Thyrogen administration to prepare them for whole body iodide scans and serum Tg measurements. In thyroidectomised thyroid cancer patients who are unable to secrete pituitary TSH upon thyroid hormone withdrawal, Thyrogen is the only acceptable method to prepare them for these procedures. Thyrogen has been used on a compassionate basis to prepare patients for radioiodine ablation. rhTSH, in addition to being useful in the management of patients with thyroid cancer, is potentially useful to test thyroid reserve and to aid in thyroid-related nuclear medicine procedures. In the future, TSH analogues that have superagonist or antagonist properties may become available as therapeutic agents.
Emerson
Charles H
CH
Department of Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts 01655, USA. charles.emmerson@umassmed.edu
Torres
Mira S T
MS
D002986:Clinical Trials as Topic; D006044:Goiter, Nodular / Q000532:radiotherapy; D006801:Humans; D007037:Hypothyroidism / Q000175:diagnosis; D007457:Iodine Radioisotopes; D018365:Neoplasm, Residual / Q000517:prevention & control; D020033:Protein Isoforms / Q000737:chemistry; D021122:Protein Subunits / Q000737:chemistry; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000532:radiotherapy / Q000628:therapy; D013965:Thyroidectomy; D013971:Thyrotoxicosis / Q000532:radiotherapy; D013972:Thyrotropin / Q000494:pharmacology* / Q000627:therapeutic use*
D007457:Iodine Radioisotopes; D020033:Protein Isoforms; D021122:Protein Subunits; D011994:Recombinant Proteins; D013972:Thyrotropin